A Phase 2 interventional study of Placebo and OBE2109 in Endometriosis, sponsored by ObsEva SA. Completed at 86 sites in 4 countries. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2022-07-21.
Sponsored by ObsEva SA · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing linzagolix in Endometriosis — none open to participants now, 1 under way, 1 of them phase 3. linzagolix · Endometriosis.
Among the 10 studies testing linzagolix in Endometriosis, this one is one of 2 that started in 2016, is one of 5 in phase 2, and was the 4th registered.
921 studies on the registry are indexed under Endometriosis; 267 are open to participants now.
Browse Endometriosis studies →None of the 10 studies testing linzagolix in Endometriosis is open now. The open studies under Endometriosis, anywhere →
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 178 Endometriosis studies recruiting now, 52 (29%) set no upper age limit and 124 (70%) stop at 75 or younger; 18 take children under 18; 39 take healthy volunteers.
This study: 18 Years to 45 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 2 started in 2016.
This study's enrollment of 328 is above the median of 67 across 541 interventional studies indexed under Endometriosis.
Median enrollment 100 across the 9 interventional studies. Of the 9 that completed or were terminated, 5 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 10 have an industry lead sponsor. The 2 most frequent:
ObsEva SA is the lead sponsor of 10 studies on the registry; none are open to participants now.
ObsEva SA has 1 study filed under Endometriosis — fewer than ten, so there is no comparison to draw.
1 of the studies testing linzagolix in Endometriosis that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07015268Phase 3Kissei Pharmaceutical Co., Ltd.A Clinical Study of KLH-2109 in Patients With Endometriosis | 2027-11 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies testing linzagolix in Endometriosis, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to assess the efficacy and safety of a range of oral doses of OBE2109 versus placebo, in reducing endometriosis associated pain.
The study is a prospective, dose-finding, randomized, parallel group, double-blind, placebo-controlled phase 2b study investigating the efficacy and safety of OBE2109 in the treatment of 330 women with moderate-to-severe endometriosis associated pain.
Subject will be randomized to one of 6 treatment groups in a 1:1:1:1:1:1 ratio (1 placebo group, 5 dose groups with different dosage/regimen).
Eligible subjects will be offered the opportunity to continue treatment with OBE2109 in an extension phase. Subjects who do not continue in the extension will enter the treatment-free follow-up phase of the study.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: OBE2109
Drug: OBE2109
Drug: OBE2109
Drug: OBE2109
Drug: OBE2109
Participants received placebo for the first 12 weeks and were then crossed-over to active treatment with OBE2109 100mg for a further 12 weeks.
Drug: Placebo · Drug: OBE2109
Placebo tablets for oral administration once daily
OBE2109 tablets for oral administration once daily
Percentage of Subjects With 30% or Greater Reduction From Baseline to Week 12 in Mean Overall Pelvic Pain Score (0-3 VRS)
The primary efficacy endpoint of the study was a response at Week 12, with response defined as a reduction of 30% or greater from baseline in the mean overall pelvic pain score, defined as the mean of daily pain scores reported in electronic diary during the preceding 28 days (4-week period), assessed on a Verbal Rating Scale for pelvic pain of 0 (no pain) to 3 (severe pain). The baseline mean score was calculated as the mean of daily scores recorded in electronic diary over the two complete menstrual cycles performed during the screening period. The relevant time points are Baseline and Week 12.
Time frame: From baseline to week 12
Change From Baseline to Week 12 in the Mean Overall Pelvic Pain Score (0-10 NRS)
This endpoint corresponds to the change from baseline to Week 12 in the mean overall pelvic pain score, defined as the mean of daily pain scores reported in electronic diary during the preceding 28 days (4-week period), assessed on a Numerical Rating Scale (NRS) for pelvic pain of 0 (no pelvic pain) to 10 (worst pelvic pain imaginable). The baseline mean score was calculated as the mean of daily scores recorded in electronic diary over the two complete menstrual cycles performed during the screening period. The relevant time points are Baseline and Week 12.
Time frame: From baseline to week 12
Percentage of Subjects With 30% or Greater Reduction From Baseline to Week 12 in Mean Pelvic Pain Scores (0-3 VRS) for Days With Uterine Bleeding
This endpoint corresponds to a response at Week 12, with response defined as a reduction of 30% or greater from baseline in the mean pelvic pain score for days with uterine bleeding/spotting, defined as the mean of daily pain scores on days with uterine bleeding/spotting recorded in electronic diary during the preceding 28 days (4-week period), assessed on a Verbal Rating Scale for pelvic pain of 0 (no pain) to 3 (severe pain). The baseline mean score was calculated as the mean of daily scores recorded in electronic diary over the two complete menstrual cycles performed during the screening period. The relevant time points are Baseline and Week 12.
Time frame: From baseline to week 12
Percentage of Subjects With 30% or Greater Reduction From Baseline to Week 12 in Mean Pelvic Pain Scores (0-3 VRS) for Days With no Uterine Bleeding
This endpoint corresponds to a response at Week 12, with response defined as a reduction of 30% or greater from baseline in the mean pelvic pain score for days with no uterine bleeding, defined as the mean of daily pain scores on days with no uterine bleeding recorded in electronic diary during the preceding 28 days (4-week period) on a Verbal Rating Scale for pelvic pain of 0 (no pain) to 3 (severe pain). The baseline mean score was calculated as the mean of daily scores recorded in electronic diary over the two complete menstrual cycles performed during the screening period. The relevant time points are Baseline and Week 12.
Time frame: From baseline to week 12
Change From Baseline to Week 12 in the Mean Dyspareunia Score (0-3 VRS)
This endpoint corresponds to the change from baseline to Week 12 in the mean dyspareunia score, defined as the mean of daily dyspareunia scores recorded in electronic diary during the preceding 28 days (4-week period), assessed on a 0-3 Verbal Rating Scale (VRS) for dyspareunia, with 0 representing "No discomfort during sexual intercourse" and 3 representing "I avoided sexual intercourse because of pain". The baseline mean score was calculated as the mean of daily scores recorded in electronic diary over the two complete menstrual cycles performed during the screening period. The dyspareunia questionnaire also included an option "not applicable: I was not sexually active for reasons other than my endometriosis or did not have sexual intercourse"; for scoring, answering "not applicable" was considered like a missing value. The relevant time points are Baseline and Week 12.
Time frame: From baseline to week 12
Change From Baseline to Week 12 in the Mean Dyschezia Score (0-10 NRS)
This endpoint corresponds to the change from baseline to week 12 in the mean dyschezia score, defined as the mean of weekly dyschezia scores reported in electronic diary during the preceding 28 days (4-week period), assessed on a 0-10 Numerical Rating Scale for dyschezia, with 0 representing no pain and 10 representing the worst pain imaginable. The baseline mean score was calculated as the mean of weekly scores recorded in electronic diary over the two complete menstrual cycles performed during the screening period. The relevant time points are Baseline and Week 12.
Time frame: From baseline to week 12
Percentage of Subjects With Any Analgesics Use at Week 12
This endpoint corresponds to the percentage of subjects at week 12 who recorded at least one pain medication intake in electronic diary during the preceding 28 days (4-week period).
Time frame: Up to week 12
Change From Baseline to Week 12 in the Mean Score of Endometriosis Health Profile-30 (EHP-30) Pain Domain
This endpoint corresponds to the change from baseline to Week 12 in the mean score of pain dimension of the EHP-30. The EHP-30 questionnaire was answered on electronic diary after activation by site staff during subject's monthly visits at site. The EHP-30 pain dimension consists of 11 items each addressing the effect of pain on various activities in the past 4 weeks and each assessed on a 5-point scale (0=Never through to 4=Always). Scaled score was equalled to total of raw score of each item in scale divided by the maximum possible raw score of all the items in the dimension, multiplied by 100, resulting in a score on a scale from 0 (best possible health status) to 100 (worst possible health status). The relevant time points are Baseline and Week 12.
Time frame: From baseline to week 12
Percentage of Subjects With Improvement in the Patient Global Impression of Change (PGIC) Score at Week 12
The PGIC questionnaire consists of one question rated on a seven point scale (1="Very Much Improved" to 7="Very Much Worse"), with which the subject had to qualify her overall status since the start of the study. The PGIC was answered on electronic diary after activation by site staff during Week 12 visit at site. This endpoint corresponds to the percentage of subjects with an "improvement" in the PGIC score, which includes all subjects who answered "Very much improved" or "Much improved" or "Minimally improved" at Week 12.
Time frame: Up to week 12
Percentage of Subjects With an Endometriosis Severity Score of "Severe" at Week 12
Subject was asked monthly on electronic diary to assess their impression of endometriosis severity, considering the preceding 4-weeks, with following possible answers: no symptoms, very mild, mild, moderate, severe. This question was programmed to raise automatically every 4 weeks on the subject electronic diary. Result reported here is the percentage of subjects who answered "severe" at week 12.
Time frame: Up to week 12
Change From Baseline to Week 12 in the Difficulty in Doing Daily Activities Mean Score
This endpoint corresponds to the change from baseline to Week 12 in the mean of daily scores for "difficulty in doing daily activities", assessed via electronic diary during the preceding 28 days (4-week period), on a Numerical Rating Scale (NRS) of 0 (no difficulty doing daily activities) to 10 (unable to do daily activities). The baseline mean score was calculated as the mean of daily scores recorded in electronic diary over the two complete menstrual cycles performed during the screening period. The relevant time points are Baseline and Week 12.
Time frame: From baseline to week 12
Percentage Change From Baseline to Week 24 in Bone Mineral Density (BMD)
Change from baseline to Week 24 in BMD assessed by dual-energy X-ray absorptiometry (DXA) scan of LUMBAR SPINE.
Time frame: From baseline up to week 24
Number of Non Benign Endometrial Biopsies at Week 24
Any pathological changes in the endometrium at week 24 were assessed from endometrial biopsies. The number of non benign biopsies at Week 24 is presented per treatment arm. Note: an isolated case of hyperplasia (without atypia) was observed at week 12 in the 200 mg group in a subject whose screening biopsy results were normal. A follow-up biopsy at week 24 revealed no abnormalities.
Time frame: Week 24
Change From Baseline to Week 24 in Endometrial Thickness Measured by Transvaginal Ultrasound (TVUS)
The endometrium thickness was measured by TVUS at screening and at Week 24 visit by the gynaecologist and result was recorded in mm. This endpoint reports the changes from baseline to Week 24 in the endometrial thickness.
Time frame: From baseline up to week 24
Percentage Change From Baseline to Week 24 in the Clinical Laboratory Assessments: LDL
This endpoint reports the change from baseline up to Week 24 in the clinical laboratory assessments: LDL cholesterol.
Time frame: From baseline up to week 24
Percentage Change From Baseline to Week 24 in Clinical Laboratory Assessments: HDL
This endpoint reports the change from baseline to week 24 in clinical laboratory assessments: HDL cholesterol.
Time frame: From Baseline up to week 24
Percentage Change From Baseline to Week 24 in Clinical Laboratory Assessments: Triglycerides
This endpoint reports the change from baseline to week 24 in clinical laboratory assessments: triglycerides.
Time frame: From baseline up to week 24
A total of 328 females were randomized at 62 sites in 4 countries: 48 sites in USA (177 subjects), 5 sites in Poland (67 subjects), 5 sites in Ukraine (73 subjects) and 4 sites in Russia (11 subjects).
| Milestone | Placebo / OBE2109 100mg | OBE2109 50mg | OBE2109 75mg FD | OBE2109 75mg TD | OBE2109 100mg | OBE2109 200mg |
|---|---|---|---|---|---|---|
| Started | 54 | 49 | 57 | 58 | 53 | 57 |
| Included in safety set | 54 | 49 | 57 | 58 | 52 | 57 |
| Included in fas | 53 | 49 | 56 | 58 | 51 | 56 |
| Completed | 45 | 45 | 53 | 51 | 45 | 49 |
| Not completed | 9 | 4 | 4 | 7 | 8 | 8 |
| Withdrew: Adverse event | 1 | 2 | 3 | 2 | 3 | 3 |
| Withdrew: Withdrawal by subject | 5 | 2 | 1 | 4 | 2 | 3 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Lost to follow-up | 3 | 0 | 0 | 0 | 0 | 2 |
| Withdrew: Other - reason not stated | 0 | 0 | 0 | 1 | 2 | 0 |
| Milestone | Placebo / OBE2109 100mg | OBE2109 50mg | OBE2109 75mg FD | OBE2109 75mg TD | OBE2109 100mg | OBE2109 200mg |
|---|---|---|---|---|---|---|
| Started | 45 | 45 | 53 | 51 | 45 | 49 |
| Completed | 37 | 41 | 48 | 46 | 39 | 42 |
| Not completed | 8 | 4 | 5 | 5 | 6 | 7 |
| Withdrew: Adverse event | 2 | 0 | 2 | 1 | 3 | 2 |
| Withdrew: Withdrawal by subject | 3 | 2 | 0 | 3 | 2 | 2 |
| Withdrew: Protocol violation | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 2 | 1 | 0 | 1 | 0 | 2 |
| Withdrew: Pregnancy | 1 | 0 | 2 | 0 | 0 | 0 |
| Withdrew: Other - reason not stated | 0 | 0 | 1 | 0 | 1 | 1 |
The primary efficacy endpoint of the study was a response at Week 12, with response defined as a reduction of 30% or greater from baseline in the mean overall pelvic pain score, defined as the mean of daily pain scores reported in electronic diary during the preceding 28 days (4-week period), assessed on a Verbal Rating Scale for pelvic pain of 0 (no pain) to 3 (severe pain). The baseline mean score was calculated as the mean of daily scores recorded in electronic diary over the two complete menstrual cycles performed during the screening period. The relevant time points are Baseline and Week 12.
| percentage of subjects | Placebo / OBE2109 100mg | OBE2109 50mg | OBE2109 75mg FD + TD | OBE2109 100mg | OBE2109 200mg |
|---|---|---|---|---|---|
| Percentage of Subjects With 30% or Greater Reduction From Baseline to Week 12 in Mean Overall Pelvic Pain Score (0-3 VRS) | 34.5 | 49.4 | 61.5 | 56.4 | 56.3 |
This endpoint corresponds to the change from baseline to Week 12 in the mean overall pelvic pain score, defined as the mean of daily pain scores reported in electronic diary during the preceding 28 days (4-week period), assessed on a Numerical Rating Scale (NRS) for pelvic pain of 0 (no pelvic pain) to 10 (worst pelvic pain imaginable). The baseline mean score was calculated as the mean of daily scores recorded in electronic diary over the two complete menstrual cycles performed during the screening period. The relevant time points are Baseline and Week 12.
| score on a scale | Placebo / OBE2109 100mg | OBE2109 50mg | OBE2109 75mg FD + TD | OBE2109 100mg | OBE2109 200mg |
|---|---|---|---|---|---|
| Change From Baseline to Week 12 in the Mean Overall Pelvic Pain Score (0-10 NRS) | -1.17 (-1.70 to -0.65) | -1.75 (-2.29 to -1.20) | -2.15 (-2.50 to -1.80) | -2.06 (-2.60 to -1.52) | -2.14 (-2.65 to -1.63) |
This endpoint corresponds to a response at Week 12, with response defined as a reduction of 30% or greater from baseline in the mean pelvic pain score for days with uterine bleeding/spotting, defined as the mean of daily pain scores on days with uterine bleeding/spotting recorded in electronic diary during the preceding 28 days (4-week period), assessed on a Verbal Rating Scale for pelvic pain of 0 (no pain) to 3 (severe pain). The baseline mean score was calculated as the mean of daily scores recorded in electronic diary over the two complete menstrual cycles performed during the screening period. The relevant time points are Baseline and Week 12.
| percentage of subjects | Placebo / OBE2109 100mg | OBE2109 50mg | OBE2109 75mg FD + TD | OBE2109 100mg | OBE2109 200mg |
|---|---|---|---|---|---|
| Percentage of Subjects With 30% or Greater Reduction From Baseline to Week 12 in Mean Pelvic Pain Scores (0-3 VRS) for Days With Uterine Bleeding | 28.5 | 43.3 | 68.2 | 68.6 | 78.9 |
This endpoint corresponds to a response at Week 12, with response defined as a reduction of 30% or greater from baseline in the mean pelvic pain score for days with no uterine bleeding, defined as the mean of daily pain scores on days with no uterine bleeding recorded in electronic diary during the preceding 28 days (4-week period) on a Verbal Rating Scale for pelvic pain of 0 (no pain) to 3 (severe pain). The baseline mean score was calculated as the mean of daily scores recorded in electronic diary over the two complete menstrual cycles performed during the screening period. The relevant time points are Baseline and Week 12.
| percentage of subjects | Placebo / OBE2109 100mg | OBE2109 50mg | OBE2109 75mg FD + TD | OBE2109 100mg | OBE2109 200mg |
|---|---|---|---|---|---|
| Percentage of Subjects With 30% or Greater Reduction From Baseline to Week 12 in Mean Pelvic Pain Scores (0-3 VRS) for Days With no Uterine Bleeding | 37.1 | 46.2 | 58.5 | 61.5 | 47.7 |
This endpoint corresponds to the change from baseline to Week 12 in the mean dyspareunia score, defined as the mean of daily dyspareunia scores recorded in electronic diary during the preceding 28 days (4-week period), assessed on a 0-3 Verbal Rating Scale (VRS) for dyspareunia, with 0 representing "No discomfort during sexual intercourse" and 3 representing "I avoided sexual intercourse because of pain". The baseline mean score was calculated as the mean of daily scores recorded in electronic diary over the two complete menstrual cycles performed during the screening period. The dyspareunia questionnaire also included an option "not applicable: I was not sexually active for reasons other than my endometriosis or did not have sexual intercourse"; for scoring, answering "not applicable" was considered like a missing value. The relevant time points are Baseline and Week 12.
| score on a scale | Placebo / OBE2109 100mg | OBE2109 50mg | OBE2109 75mg FD + TD | OBE2109 100mg | OBE2109 200mg |
|---|---|---|---|---|---|
| Change From Baseline to Week 12 in the Mean Dyspareunia Score (0-3 VRS) | -0.39 (-0.63 to -0.16) | -0.62 (-0.87 to -0.37) | -0.59 (-0.76 to -0.43) | -0.66 (-0.91 to -0.41) | -0.79 (-1.03 to -0.54) |
This endpoint corresponds to the change from baseline to week 12 in the mean dyschezia score, defined as the mean of weekly dyschezia scores reported in electronic diary during the preceding 28 days (4-week period), assessed on a 0-10 Numerical Rating Scale for dyschezia, with 0 representing no pain and 10 representing the worst pain imaginable. The baseline mean score was calculated as the mean of weekly scores recorded in electronic diary over the two complete menstrual cycles performed during the screening period. The relevant time points are Baseline and Week 12.
| score on a scale/week | Placebo / OBE2109 100mg | OBE2109 50mg | OBE2109 75mg FD + TD | OBE2109 100mg | OBE2109 200mg |
|---|---|---|---|---|---|
| Change From Baseline to Week 12 in the Mean Dyschezia Score (0-10 NRS) | -0.78 (-1.34 to -0.22) | -1.55 (-2.14 to -0.96) | -1.87 (-2.25 to -1.49) | -1.97 (-2.55 to -1.39) | -1.7 (-2.25 to -1.15) |
This endpoint corresponds to the percentage of subjects at week 12 who recorded at least one pain medication intake in electronic diary during the preceding 28 days (4-week period).
| percentage of subjects | Placebo / OBE2109 100mg | OBE2109 50mg | OBE2109 75mg FD + TD | OBE2109 100mg | OBE2109 200mg |
|---|---|---|---|---|---|
| Percentage of Subjects With Any Analgesics Use at Week 12 | 90.6 (78.6 to 96.2) | 77.1 (62.7 to 87.1) | 74.8 (65.7 to 82.1) | 68.8 (54.1 to 80.5) | 72.1 (58.4 to 82.7) |
This endpoint corresponds to the change from baseline to Week 12 in the mean score of pain dimension of the EHP-30. The EHP-30 questionnaire was answered on electronic diary after activation by site staff during subject's monthly visits at site. The EHP-30 pain dimension consists of 11 items each addressing the effect of pain on various activities in the past 4 weeks and each assessed on a 5-point scale (0=Never through to 4=Always). Scaled score was equalled to total of raw score of each item in scale divided by the maximum possible raw score of all the items in the dimension, multiplied by 100, resulting in a score on a scale from 0 (best possible health status) to 100 (worst possible health status). The relevant time points are Baseline and Week 12.
| score on a scale | Placebo / OBE2109 100mg | OBE2109 50mg | OBE2109 75mg FD + TD | OBE2109 100mg | OBE2109 200mg |
|---|---|---|---|---|---|
| Change From Baseline to Week 12 in the Mean Score of Endometriosis Health Profile-30 (EHP-30) Pain Domain | -7.4 (-12.36 to -2.41) | -18.5 (-23.44 to -13.47) | -18.9 (-22.20 to -15.69) | -19.4 (-24.28 to -14.55) | -20.9 (-25.69 to -16.10) |
The PGIC questionnaire consists of one question rated on a seven point scale (1="Very Much Improved" to 7="Very Much Worse"), with which the subject had to qualify her overall status since the start of the study. The PGIC was answered on electronic diary after activation by site staff during Week 12 visit at site. This endpoint corresponds to the percentage of subjects with an "improvement" in the PGIC score, which includes all subjects who answered "Very much improved" or "Much improved" or "Minimally improved" at Week 12.
| percentage of subjects | Placebo / OBE2109 100mg | OBE2109 50mg | OBE2109 75mg FD + TD | OBE2109 100mg | OBE2109 200mg |
|---|---|---|---|---|---|
| Percentage of Subjects With Improvement in the Patient Global Impression of Change (PGIC) Score at Week 12 | 65.1 | 78.6 | 80.6 | 86 | 95.7 |
Subject was asked monthly on electronic diary to assess their impression of endometriosis severity, considering the preceding 4-weeks, with following possible answers: no symptoms, very mild, mild, moderate, severe. This question was programmed to raise automatically every 4 weeks on the subject electronic diary. Result reported here is the percentage of subjects who answered "severe" at week 12.
| percentage of subjects | Placebo / OBE2109 100mg | OBE2109 50mg | OBE2109 75mg FD + TD | OBE2109 100mg | OBE2109 200mg |
|---|---|---|---|---|---|
| Percentage of Subjects With an Endometriosis Severity Score of "Severe" at Week 12 | 20.9 | 4.5 | 7.8 | 4.5 | 4.2 |
This endpoint corresponds to the change from baseline to Week 12 in the mean of daily scores for "difficulty in doing daily activities", assessed via electronic diary during the preceding 28 days (4-week period), on a Numerical Rating Scale (NRS) of 0 (no difficulty doing daily activities) to 10 (unable to do daily activities). The baseline mean score was calculated as the mean of daily scores recorded in electronic diary over the two complete menstrual cycles performed during the screening period. The relevant time points are Baseline and Week 12.
| score on a scale | Placebo / OBE2109 100mg | OBE2109 50mg | OBE2109 75mg FD + TD | OBE2109 100mg | OBE2109 200mg |
|---|---|---|---|---|---|
| Change From Baseline to Week 12 in the Difficulty in Doing Daily Activities Mean Score | -1.17 (-1.68 to -0.65) | -1.65 (-2.18 to -1.12) | -2.06 (-2.41 to -1.72) | -1.88 (-2.41 to -1.36) | -1.99 (-2.49 to -1.49) |
Change from baseline to Week 24 in BMD assessed by dual-energy X-ray absorptiometry (DXA) scan of LUMBAR SPINE.
| percentage change | Placebo / OBE2109 100mg | OBE2109 50mg | OBE2109 75mg FD | OBE2109 75mg TD | OBE2109 100mg | OBE2109 200mg |
|---|---|---|---|---|---|---|
| Percentage Change From Baseline to Week 24 in Bone Mineral Density (BMD) | -0.929 (-1.71 to -0.15) | 0.137 (-0.83 to 1.11) | -0.798 (-1.57 to -0.03) | -1.000 (-1.71 to -0.29) | -1.365 (-2.14 to -0.59) | -2.602 (-3.56 to -1.65) |
Any pathological changes in the endometrium at week 24 were assessed from endometrial biopsies. The number of non benign biopsies at Week 24 is presented per treatment arm. Note: an isolated case of hyperplasia (without atypia) was observed at week 12 in the 200 mg group in a subject whose screening biopsy results were normal. A follow-up biopsy at week 24 revealed no abnormalities.
| Non benign biopsies | Placebo / OBE2109 100mg | OBE2109 50mg | OBE2109 75mg FD | OBE2109 75mg TD | OBE2109 100mg | OBE2109 200mg |
|---|---|---|---|---|---|---|
| Number of Non Benign Endometrial Biopsies at Week 24 | 0 | 0 | 0 | 0 | 0 | 0 |
The endometrium thickness was measured by TVUS at screening and at Week 24 visit by the gynaecologist and result was recorded in mm. This endpoint reports the changes from baseline to Week 24 in the endometrial thickness.
| mm | Placebo / OBE2109 100mg | OBE2109 50mg | OBE2109 75mg FD | OBE2109 75mg TD | OBE2109 100mg | OBE2109 200mg |
|---|---|---|---|---|---|---|
| Change From Baseline to Week 24 in Endometrial Thickness Measured by Transvaginal Ultrasound (TVUS) | -3.1 ± 4.64 | -1.5 ± 4.28 | -2.3 ± 4.15 | -1.3 ± 3.70 | -1.6 ± 4.56 | -4.0 ± 3.39 |
This endpoint reports the change from baseline up to Week 24 in the clinical laboratory assessments: LDL cholesterol.
| percent change | Placebo / OBE2109 100mg | OBE2109 50mg | OBE2109 75mg FD | OBE2109 75mg TD | OBE2109 100mg | OBE2109 200mg |
|---|---|---|---|---|---|---|
| Percentage Change From Baseline to Week 24 in the Clinical Laboratory Assessments: LDL | 1.7 ± 15.7 | -0.3 ± 16.6 | 7.4 ± 55.2 | 7.3 ± 21.4 | 9.7 ± 20.7 | 10.3 ± 21.7 |
This endpoint reports the change from baseline to week 24 in clinical laboratory assessments: HDL cholesterol.
| percent change | Placebo / OBE2109 100mg | OBE2109 50mg | OBE2109 75mg FD | OBE2109 75mg TD | OBE2109 100mg | OBE2109 200mg |
|---|---|---|---|---|---|---|
| Percentage Change From Baseline to Week 24 in Clinical Laboratory Assessments: HDL | 5.5 ± 11.7 | 2.9 ± 12.9 | 3.8 ± 17.8 | 6.2 ± 24.1 | 5.6 ± 18.0 | 8.1 ± 14.7 |
This endpoint reports the change from baseline to week 24 in clinical laboratory assessments: triglycerides.
| percent change | Placebo / OBE2109 100mg | OBE2109 50mg | OBE2109 75mg FD | OBE2109 75mg TD | OBE2109 100mg | OBE2109 200mg |
|---|---|---|---|---|---|---|
| Percentage Change From Baseline to Week 24 in Clinical Laboratory Assessments: Triglycerides | 17.9 ± 38.6 | 16.4 ± 41.3 | 5.2 ± 35.2 | 13.6 ± 45.0 | 20.5 ± 80.6 | 24.0 ± 57.7 |
Collected over From baseline up to week 24. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo BL-Wk12 | 0/55 (0%) | 1/55 (1.8%) | 22/55 (40%) |
| OBE2109 100mg Wk12-Wk24 | 0/55 (0%) | 0/55 (0%) | 19/55 (34.5%) |
| OBE2109 50mg BL-Wk24 | 0/49 (0%) | 1/49 (2%) | 27/49 (55.1%) |
| OBE2109 75mg FD BL-Wk24 | 0/58 (0%) | 0/58 (0%) | 30/58 (51.7%) |
| OBE2109 75mg TD BL-Wk24 | 0/56 (0%) | 0/56 (0%) | 36/56 (64.3%) |
| OBE2109 100mg BL-Wk24 | 0/52 (0%) | 3/52 (5.8%) | 31/52 (59.6%) |
| OBE2109 200mg BL-Wk24 | 0/57 (0%) | 1/57 (1.8%) | 39/57 (68.4%) |
| Event | Placebo BL-Wk12 | OBE2109 100mg Wk12-Wk24 | OBE2109 50mg BL-Wk24 | OBE2109 75mg FD BL-Wk24 | OBE2109 75mg TD BL-Wk24 | OBE2109 100mg BL-Wk24 | OBE2109 200mg BL-Wk24 |
|---|---|---|---|---|---|---|---|
| Pyelonephritis acuteInfections and infestations | 0/55 | 0/55 | 1/49 | 0/58 | 0/56 | 0/52 | 0/57 |
| Ectopic pregnancyPregnancy, puerperium and perinatal conditions | 0/55 | 0/55 | 0/49 | 0/58 | 0/56 | 1/52 | 0/57 |
| EnterocolitisGastrointestinal disorders | 0/55 | 0/55 | 0/49 | 0/58 | 0/56 | 1/52 | 0/57 |
| MetrorrhagiaReproductive system and breast disorders | 0/55 | 0/55 | 0/49 | 0/58 | 0/56 | 1/52 | 0/57 |
| Stab woundInjury, poisoning and procedural complications | 1/55 | 0/55 | 0/49 | 0/58 | 0/56 | 0/52 | 0/57 |
| Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders | 0/55 | 0/55 | 0/49 | 0/58 | 0/56 | 0/52 | 1/57 |
| Event | Placebo BL-Wk12 | OBE2109 100mg Wk12-Wk24 | OBE2109 50mg BL-Wk24 | OBE2109 75mg FD BL-Wk24 | OBE2109 75mg TD BL-Wk24 | OBE2109 100mg BL-Wk24 | OBE2109 200mg BL-Wk24 |
|---|---|---|---|---|---|---|---|
| hot flushVascular disorders | 6/55 | 5/55 | 9/49 | 11/58 | 13/56 | 15/52 | 26/57 |
| headacheNervous system disorders | 14/55 | 9/55 | 12/49 | 10/58 | 16/56 | 15/52 | 17/57 |
| nasopharyngitisInfections and infestations | 3/55 | 1/55 | 8/49 | 7/58 | 4/56 | 2/52 | 1/57 |
| arthralgiaMusculoskeletal and connective tissue disorders | 0/55 | 0/55 | 1/49 | 0/58 | 1/56 | 3/52 | 9/57 |
| nauseaGastrointestinal disorders | 1/55 | 0/55 | 3/49 | 2/58 | 2/56 | 4/52 | 7/57 |
| mood swingsPsychiatric disorders | 5/55 | 1/55 | 2/49 | 1/58 | 3/56 | 3/52 | 2/57 |
| blood creatine phosphokinase increasedInvestigations | 1/55 | 1/55 | 1/49 | 4/58 | 5/56 | 2/52 | 4/57 |
| urinary tract infectionInfections and infestations | 0/55 | 0/55 | 1/49 | 3/58 | 3/56 | 2/52 | 5/57 |
| abdominal pain upperGastrointestinal disorders | 1/55 | 2/55 | 1/49 | 0/58 | 1/56 | 4/52 | 1/57 |
| fatigueGeneral disorders | 0/55 | 0/55 | 1/49 | 0/58 | 0/56 | 4/52 | 2/57 |
| Age, Categorical(Participants) | Placebo / OBE2109 100mg | OBE2109 50mg | OBE2109 75mg FD | OBE2109 75mg TD | OBE2109 100mg | OBE2109 200mg | Total |
|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 53 | 49 | 56 | 58 | 51 | 56 | 323 |
| >=65 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Age, Continuous(years) | Placebo / OBE2109 100mg | OBE2109 50mg | OBE2109 75mg FD | OBE2109 75mg TD | OBE2109 100mg | OBE2109 200mg | Total |
|---|---|---|---|---|---|---|---|
| Mean | 32.4 ± 5.78 | 30.9 ± 5.98 | 32.0 ± 6.83 | 31.2 ± 5.85 | 33.0 ± 5.78 | 30.9 ± 6.03 | 31.7 ± 6.06 |
| Sex: Female, Male(Participants) | Placebo / OBE2109 100mg | OBE2109 50mg | OBE2109 75mg FD | OBE2109 75mg TD | OBE2109 100mg | OBE2109 200mg | Total |
|---|---|---|---|---|---|---|---|
| Female | 53 | 49 | 56 | 58 | 51 | 56 | 323 |
| Male | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Placebo / OBE2109 100mg | OBE2109 50mg | OBE2109 75mg FD | OBE2109 75mg TD | OBE2109 100mg | OBE2109 200mg | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 3 | 5 | 3 | 7 | 4 | 5 | 27 |
| Not Hispanic or Latino | 25 | 18 | 27 | 25 | 24 | 23 | 142 |
| Unknown or Not Reported | 25 | 26 | 26 | 26 | 23 | 28 | 154 |
| Race (NIH/OMB)(Participants) | Placebo / OBE2109 100mg | OBE2109 50mg | OBE2109 75mg FD | OBE2109 75mg TD | OBE2109 100mg | OBE2109 200mg | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 4 | 2 | 5 | 8 | 3 | 3 | 25 |
| White | 49 | 46 | 50 | 50 | 46 | 52 | 293 |
| More than one race | 0 | 1 | 1 | 0 | 2 | 1 | 5 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jul 2016 to primary completion in Apr 2018, 21 months.
Results were first posted in Jul 2022, 4 years 3 months after primary completion. A results delay was requested in May 2019.
Of 44 phase 2 interventional studies under Endometriosis, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 37. This study's 21 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Linzagolix
ObsEva SA